...
首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach
【24h】

Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach

机译:掺入叶酸接枝的固体脂质纳米粒子的pH响应藻酸盐微珠的口服递送表现出对结直肠癌的增强靶向效果:双重针对性的方法

获取原文
获取原文并翻译 | 示例
           

摘要

To achieve an enhanced anticancer effect of drug to treat colorectal cancer, a dual-targeted (i.e., ligand-tailored and pH-triggered) multiparticulate system has been designed to deliver drug directly into the colon domain. In this regard, folic acid-grafted solid lipid nanoparticles (SLNs) bearing irinotecan were encapsulated in microbeads of alginates. Afterward, these microbeads were coated with enteric polymer (i.e., Eudragit 5100) to make them pH-responsive. COLO-205 cells were used to determine in vitro cytotoxidty potential of various formulations. Findings for IHT loaded FA-coupled SLNs suggested significantly (p < 0.05) higher cytotoxic effect against COLO-205 cells (in vitro) as compared to drug solution and uncoupled SLNs. Further, the microbeads incorporating SLNs were evaluated for drug release in various simulated gastrointestinal fluids (i.e., 01,12,4.5,7.4, and 6.8). Findings confirmed the release of the drug in the intestinal region only (i.e., pH > 7.0). In therapeutic experiments (in vivo). the optimized radiolabeled microbeads (Tc-99m-EuBIRSLN3 and Tc-99m-EuBIRSLNF3) were administered via oral route to Balb/c mice. The results suggested that FA-coupled microbeads (Tc-99m-EuBIRSLNF3) distributed higher (19.62 +/- 0.78%) amount of drug (i.e., Tc-99m-IHT/g of tissue) as compared to uncoupled microbeads (Tc-99(m)-EuBIRSLN3, 7.63 +/- 0.49%) in the colon tumor after 48 h, which confirmed its targeting ability to the tumor in the colon region. Further, Tc-99(m)-EuBIRSLNF3 showed significantly (p < 0.01) higher antitumor effect against HT-29 cells bearing Balb/c mice over uncoupled microbeads and advocated their potential for enhanced antitumor efficacy for the treatment of colorectal cancer. (C) 2020 Elsevier B.V. All rights reserved.
机译:为了实现药物的增强抗癌效果治疗结肠直肠癌,双靶向(即配体定制和pH-触发)的多颗粒系统已经设计成直接将药物直接输送到结肠结构域中。在这方面,叶酸接枝的固体脂质纳米颗粒(SLNS)含有氨基丙烷的含量在藻酸盐的微珠中。之后,将这些微珠涂有肠溶聚合物(即Eudragit 5100)以使其pH-响应。 COLO-205细胞用于确定各种制剂的体外细胞毒潜力。与药物溶液和未耦合的SLN相比,IHT加载的FA耦合SLN的发现显着(P <0.05)对COLO-205细胞(体外)的较高细胞毒性效应。此外,在各种模拟的胃肠流体中评价包含SLNS的微生物释放(即01,12,4.5,7.4和6.8)。发现证实了仅在肠区中释放药物(即pH> 7.0)。在治疗实验中(体内)。通过口腔途径向BALB / C小鼠施用优化的放射性标记微珠(TC-99M-EUBIRSLN3和TC-99M-EUBIRSLNF3)。结果表明,FA-耦合微珠(TC - 99m的-EuBIRSLNF3)分布较高(19.62 +/- 0.78%)的药物量(即,锝 - 99m的-IHT / g组织)相比,未偶联的微珠(TC-99 (m)-eubirsln3,7.63 +/- 0.49%)在48小时后在结肠肿瘤中,这证实了其靶向结肠区肿瘤的靶向能力。此外,TC-99(m)-eubirslNF3显着(p <0.01)对HT-29细胞的抗肿瘤效果显着(p <0.01)抗HER-29细胞在未耦合的微珠上,并主张它们对治疗结肠直肠癌的增强抗肿瘤功效的可能性。 (c)2020 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号